Background Human epidermal growth factor receptor 2 (HER2), a promising therapeutic
target, can be mutated, amplified, or overexpressed in different malignancies, including non …

BACKGROUND Prognostic implications of overexpression of the HER‐2 gene in nonsmall
cell lung carcinoma (NSCLC) are a matter of controversy. Many conflicting results have been …

Aim: The human epidermal growth factor receptor HER-2/neu (HER2) gene is a proto-
oncogene involved in the signal transduction pathways leading to cell growth and …

[Non-small cell lung cancer: HER2 oncogene status]. - Abstract - Europe PMC Sign in | Create an
account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk …

Introduction We aim to investigate the relationship between HER2 gene phenotype and
clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) …

The expression of human epidermal growth factor receptor 2 (HER2) is related to tumor
progression in many human malignancies. This study evaluated the significance of HER2 in …

Purpose Human epidermal growth factor 2 (HER2) alterations are found in approximately
2%–5% of non-small cell lung cancer (NSCLC). This study aimed to evaluate the clinical …

Lung cancer is the leading cause of mortality worldwide. The median survival of advanced
disease is in the range of 8 to 10 months. Intrinsic or acquired drug resistance pose major …

Objectives While novel anti-human epidermal growth factor receptor 2 (HER2) agents have
recently been developed, no definite criteria have been proposed as indications for the use …

Introduction The prognostic value of HER2 expression in patients with advanced non-small
cell lung cancer remains controversial. The relationship between HER2 expression, and …